Objective Hepatitis C is an important risk factor for cirrhosis and liver cancer in the Taiwanese population. Domestic prisons reported a higher rate of hepatitis C infection than the
Paritaprevir (PTV) is a non-structural protein 3/4A protease inhibitor developed for the treatment of hepatitis C disease as a fixed dose combination of ombitasvir (OBV) and ritonavir (RTV) with or wi
Hb, hemoglobin; SVR12, sustained virological response (undetectable HCV RNA) at 12 weeks post-treatment; TID16W/TID28W/TID40W, faldaprevir 120 mg once daily and deleobuvir 600 mg three times daily plu
This data archive contains the following 7 files relating to treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: - Supplementary figure 1: Thematic map